Please login to the form below

Not currently logged in
Email:
Password:

XenoPort

This page shows the latest XenoPort news and features for those working in and with pharma, biotech and healthcare.

Reckitt Benckiser confirms pharma spin-off plans

Reckitt Benckiser confirms pharma spin-off plans

called arbaclofen placarbil - which was licensed in May from XenoPort.

Latest news

  • Publicis adds Heartbeat to portfolio Publicis adds Heartbeat to portfolio

    Clients included Galderma, Janssen Pharmaceuticals, Novartis, Pfizer, Sanofi, Teva and XenoPort.

  • US shortage of GSK’s restless legs syndrome treatment Horizant US shortage of GSK’s restless legs syndrome treatment Horizant

    In its notice, the US regulator said GSK is “ experiencing a backorder situation”, leaving an expected shortage of Horizant (gabapentin enacarbil) until June 2013 – one month after XenoPort assumes responsibility for ... Then in November 2012, GSK

  • GSK and XenoPort end restless legs syndrome collaboration GSK and XenoPort end restless legs syndrome collaboration

    GSK and XenoPort end restless legs syndrome collaboration. Follows tough approval period for Horizant and subsequent poor sales . ... XenoPort will not receive any revenue or incur any losses from these sales.

  • Horizant gets post-shingles pain indication in US

    Horizant gets post-shingles pain indication in US. FDA approval comes as XenoPort and partner GlaxoSmithKline remain in dispute over commercial activities to promote drug. ... Prescriptions have been disappointing however, and towards the end of last

  • GSK Restless Legs Syndrome drug approved

    GSK Restless Legs Syndrome drug approved. GlaxoSmithKline and XenoPort have won marketing approval from the US Food and Drug Administration for Horizant, a treatment for moderate-to-severe primary Restless Legs ... The drug, which was discovered and

More from news
Approximately 2 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Deal Watch May 2016 Deal Watch May 2016

    399-616. Xenoport/ Arbor Pharmaceuticals. Corporate acquisition. Acquisition for $7.03 per share [60% premium]; includes Horizant [gabapentin] for restless legs.

  • Deal Watch March 2016 Deal Watch March 2016

    Two deals involved products at a later stage of development: Dr Reddy's licence for Xenoport's phase II product XP23829 for plaque psoriasis, and Ipsen's licence for Exelixis's ... Collaboration – development. $595. Xenoport/ Dr Reddy's. XP-23829 for

  • Deal Watch table for May 2014 Deal Watch table for May 2014

    260+. Xenoport / Reckitt Benckiser. Development and commercialisation licence. Arbaclofen placarbil end pIIa for alcohol use disorders.

  • Pharma deals during May 2014 Pharma deals during May 2014

    It is therefore very surprising that this month Reckitt Benckiser announced two deals relating to addiction products: a $145m deal with Xenoport for arbaclofen placarbil at end phase IIa for treatment ... In addition to the Xenoport deal reported above,

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • XenoPort appoints chief medical officer XenoPort appoints chief medical officer

    XenoPort appoints chief medical officer. Richard Kim led Tysabri programme at Biogen Idec. ... XenoPort has appointed Dr Richard Kim as chief medical officer and senior VP, clinical development and medical affairs.

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics